AI Drug Discovery Startup Converge Bio Raises $25M in Series A Funding

Converge Bio, a startup focused on AI-driven drug discovery, has raised $25 million in a Series A funding round led by Bessemer Venture Partners. The funding round also saw participation from executives at Meta, OpenAI, and Wiz.

The funding will be used to further develop Converge Bio's AI-powered platform for discovering new drugs. The platform uses machine learning algorithms to analyze large amounts of data and identify potential drug candidates.

Converge Bio's platform has already shown promising results in identifying new drug candidates for various diseases, including cancer and neurological disorders. The company's AI-powered approach has the potential to revolutionize the drug discovery process, making it faster and more efficient.

The funding round is a significant milestone for Converge Bio, which was founded in 2020 by a team of researchers and entrepreneurs. The company has already made significant progress in developing its AI-powered platform and has attracted the attention of top investors in the industry.

The Series A funding round is a testament to the growing interest in AI-driven drug discovery and the potential of Converge Bio's platform to transform the pharmaceutical industry.

Sources

[3] Converge Bio raises $25M, backed by Bessemer and execs from Meta, OpenAI, Wiz